CDX
HT-1376
Tumor indication
Bladder
Description
HT-1376 (Bladder Cancer CDX Model)
The HT-1376 bladder cancer line was derived from a patient with grade III transitional cell carcinoma. It represents advanced bladder cancer biology. HT-1376 has been applied in drug discovery and biomarker research. Its reproducibility ensures consistent outcomes in bladder cancer translational pipelines.
Key Features:
- Derived from grade III transitional cell carcinoma.
- Represents advanced urothelial carcinoma.
- Epithelial carcinoma morphology.
- Tumorigenic in xenografts.
Applications:
HT-1376 is used to evaluate novel therapies for bladder cancer. Researchers apply it in biomarker validation and resistance mechanism studies. It supports screening of targeted and cytotoxic agents. Its reproducibility makes it a trusted model for bladder cancer pipelines.
Details
- Tumor indication
- Bladder
- Organism
- Human
- Mouse sex
- Female
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.